FDA Decries Erectile Dysfunction Drug Promo In New Warning

Law360 (August 26, 2019, 8:00 PM EDT) -- Metuchen Pharmaceuticals LLC improperly promoted its erectile dysfunction drug by erroneously claiming it can help reduce the risk of heart failure and neglecting to mention that it can cause irreversible erectile tissue damage, the U.S. Food and Drug Administration said in its first warning letter of the year.

The written rebuke from the FDA, which the Office of Prescription Drug Promotion quietly released Monday, focused on advertisements touting the benefits of Stendra for men with erectile dysfunction. Banner advertisements on adult websites stating the tablet can help men “get hard & stay hard” to “indulge in life’s sweet pleasures whenever you...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS